1. CRA-026440 inhibits the growth of human tumor xenografts in vivo.
CRA inhibits the growth of human tumor xenografts in vivo. The growth of tumors over time is plotted in (A) U937 histiocytic tumor xenograft model (vehicle alone, ♦; 100 mg/kg, ×; 50 mg/kg, ▴; 25 mg/kg, ▪), (B) HCT 116 colon tumor xenograft model (vehicle alone, ♦; 150 mg/kg, ◊; 100 mg/kg, ×; 75 mg/kg, ▴; 50 mg/kg, ▪), (C) HCT116 colon tumor xenograft model (vehicle alone, ♦; 50 mg/kg qdx4/wk, ▪; 67 mg/kg qdx3/wk, □; 100 mg/kg qdx2/wk, ×; 100 mg/kg Monday + Friday/wk, ◊), (D) HCT 116 colon tumor xenograft model (vehicle alone, ♦; 25 mg/kg, ▴; 50 mg/kg, ▪; Avastin 25 mg/kg, ×; Avastin + CRA at 25 mg/kg, ▵; Avastin + CRA at 50 mg/kg, □). Ki67 immunohistochemical analysis: (E) HCT 116 xenograft tumors with three daily i.v. treatment of vehicle, (F) HCT 116 xenograft tumors with three daily i.v. treatment of CRA at 100 mg/kg. Error bars were calculated as described in Materials and Methods. *, P < 0.05; **, P < 0.01.
Z. Alexander Cao et al. Mol Cancer Ther 2006;5:
©2006 by American Association for Cancer Research